Cargando…

hsa-miR-206b Involves in the Development of Papillary Thyroid Carcinoma via Targeting LMX1B

OBJECTIVES: Papillary thyroid carcinoma (PTC) is the most common endocrine system malignant thyroid cancer, and patients with lymph node metastasis typically exhibit poor prognosis. MicroRNAs (miRNAs) can act as either oncogenes or tumor suppressors in PTC. This study was aimed at using PTC transcri...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Hongsheng, Zhu, Chumeng, Ruan, Yanyun, Fan, Lilong, Ruan, Zhengying, Chen, Qi, Yuan, Jiuyun, Xu, Yang, Wang, Hongwei, Wei, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948606/
https://www.ncbi.nlm.nih.gov/pubmed/35342753
http://dx.doi.org/10.1155/2022/7488708
_version_ 1784674693251334144
author Lu, Hongsheng
Zhu, Chumeng
Ruan, Yanyun
Fan, Lilong
Ruan, Zhengying
Chen, Qi
Yuan, Jiuyun
Xu, Yang
Wang, Hongwei
Wei, Qing
author_facet Lu, Hongsheng
Zhu, Chumeng
Ruan, Yanyun
Fan, Lilong
Ruan, Zhengying
Chen, Qi
Yuan, Jiuyun
Xu, Yang
Wang, Hongwei
Wei, Qing
author_sort Lu, Hongsheng
collection PubMed
description OBJECTIVES: Papillary thyroid carcinoma (PTC) is the most common endocrine system malignant thyroid cancer, and patients with lymph node metastasis typically exhibit poor prognosis. MicroRNAs (miRNAs) can act as either oncogenes or tumor suppressors in PTC. This study was aimed at using PTC transcriptome data obtained from The Cancer Genome Atlas (TCGA) to identify differentially expressed, survival-related miRNAs and target genes. METHODS: We analyzed the TCGA datasets to identify differentially expressed mRNAs/miRNAs in 493 PTC patients with stage I_II group (stages I and II) versus stage III_IV group (stages III and IV) according to TNM staging. The Kaplan-Meier survival analysis, the Cox regression analysis, and the log-rank test were performed to investigate survival-related miRNAs. RESULTS: We identified 36 significantly differentially expressed miRNAs in the stage I_II group versus the stage III_IV group, in which 31 were upregulated and only 5 were downregulated (i.e., hsa-miR-891a-5p, hsa-miR-892a, hsa-miR-888-5p, hsa-miR-891b, and hsa-miR-892b). Additionally, five signature miRNAs (hsa-miR-206, hsa-miR-299-3p, hsa-miR-299-5p, hsa-miR-496, and hsa-miR-509-3-5p) were associated with the overall survival of PTC patients. We also found that LMX1B, whose expression was inversely correlated with hsa-miR-206 expression, was a putative target gene of hsa-miR-206 and LMX1B was likely to serve as a tumor suppressor in PTC. CONCLUSION: hsa-miR-206b might be involved in promoting TNM staging in PTC via targeting of LMX1B.
format Online
Article
Text
id pubmed-8948606
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-89486062022-03-26 hsa-miR-206b Involves in the Development of Papillary Thyroid Carcinoma via Targeting LMX1B Lu, Hongsheng Zhu, Chumeng Ruan, Yanyun Fan, Lilong Ruan, Zhengying Chen, Qi Yuan, Jiuyun Xu, Yang Wang, Hongwei Wei, Qing Biomed Res Int Research Article OBJECTIVES: Papillary thyroid carcinoma (PTC) is the most common endocrine system malignant thyroid cancer, and patients with lymph node metastasis typically exhibit poor prognosis. MicroRNAs (miRNAs) can act as either oncogenes or tumor suppressors in PTC. This study was aimed at using PTC transcriptome data obtained from The Cancer Genome Atlas (TCGA) to identify differentially expressed, survival-related miRNAs and target genes. METHODS: We analyzed the TCGA datasets to identify differentially expressed mRNAs/miRNAs in 493 PTC patients with stage I_II group (stages I and II) versus stage III_IV group (stages III and IV) according to TNM staging. The Kaplan-Meier survival analysis, the Cox regression analysis, and the log-rank test were performed to investigate survival-related miRNAs. RESULTS: We identified 36 significantly differentially expressed miRNAs in the stage I_II group versus the stage III_IV group, in which 31 were upregulated and only 5 were downregulated (i.e., hsa-miR-891a-5p, hsa-miR-892a, hsa-miR-888-5p, hsa-miR-891b, and hsa-miR-892b). Additionally, five signature miRNAs (hsa-miR-206, hsa-miR-299-3p, hsa-miR-299-5p, hsa-miR-496, and hsa-miR-509-3-5p) were associated with the overall survival of PTC patients. We also found that LMX1B, whose expression was inversely correlated with hsa-miR-206 expression, was a putative target gene of hsa-miR-206 and LMX1B was likely to serve as a tumor suppressor in PTC. CONCLUSION: hsa-miR-206b might be involved in promoting TNM staging in PTC via targeting of LMX1B. Hindawi 2022-03-15 /pmc/articles/PMC8948606/ /pubmed/35342753 http://dx.doi.org/10.1155/2022/7488708 Text en Copyright © 2022 Hongsheng Lu et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lu, Hongsheng
Zhu, Chumeng
Ruan, Yanyun
Fan, Lilong
Ruan, Zhengying
Chen, Qi
Yuan, Jiuyun
Xu, Yang
Wang, Hongwei
Wei, Qing
hsa-miR-206b Involves in the Development of Papillary Thyroid Carcinoma via Targeting LMX1B
title hsa-miR-206b Involves in the Development of Papillary Thyroid Carcinoma via Targeting LMX1B
title_full hsa-miR-206b Involves in the Development of Papillary Thyroid Carcinoma via Targeting LMX1B
title_fullStr hsa-miR-206b Involves in the Development of Papillary Thyroid Carcinoma via Targeting LMX1B
title_full_unstemmed hsa-miR-206b Involves in the Development of Papillary Thyroid Carcinoma via Targeting LMX1B
title_short hsa-miR-206b Involves in the Development of Papillary Thyroid Carcinoma via Targeting LMX1B
title_sort hsa-mir-206b involves in the development of papillary thyroid carcinoma via targeting lmx1b
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948606/
https://www.ncbi.nlm.nih.gov/pubmed/35342753
http://dx.doi.org/10.1155/2022/7488708
work_keys_str_mv AT luhongsheng hsamir206binvolvesinthedevelopmentofpapillarythyroidcarcinomaviatargetinglmx1b
AT zhuchumeng hsamir206binvolvesinthedevelopmentofpapillarythyroidcarcinomaviatargetinglmx1b
AT ruanyanyun hsamir206binvolvesinthedevelopmentofpapillarythyroidcarcinomaviatargetinglmx1b
AT fanlilong hsamir206binvolvesinthedevelopmentofpapillarythyroidcarcinomaviatargetinglmx1b
AT ruanzhengying hsamir206binvolvesinthedevelopmentofpapillarythyroidcarcinomaviatargetinglmx1b
AT chenqi hsamir206binvolvesinthedevelopmentofpapillarythyroidcarcinomaviatargetinglmx1b
AT yuanjiuyun hsamir206binvolvesinthedevelopmentofpapillarythyroidcarcinomaviatargetinglmx1b
AT xuyang hsamir206binvolvesinthedevelopmentofpapillarythyroidcarcinomaviatargetinglmx1b
AT wanghongwei hsamir206binvolvesinthedevelopmentofpapillarythyroidcarcinomaviatargetinglmx1b
AT weiqing hsamir206binvolvesinthedevelopmentofpapillarythyroidcarcinomaviatargetinglmx1b